Open Label Study to Test the Safety and Efficacy of Ustekinumab in Patients With Giant Cell Arteritis
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Prednisone (Primary) ; Ustekinumab (Primary)
- Indications Giant cell arteritis
- Focus Therapeutic Use
- Acronyms UGCA
- 16 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.
- 16 Feb 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2020.
- 16 Feb 2017 Status changed from not yet recruiting to recruiting.